Mirum Pharmaceuticals, Inc. announced that on April 5, 2023, the Board, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Timothy Walbert to the Board, effective immediately. Mr. Walbert will serve as a Class I director, with an initial term expiring at the Company's 2023 Annual Meeting of Stockholders. On April 5, 2023, Niall O'Donnell, Ph.D., notified the board of directors (the “Board”) of Mirum Pharmaceuticals, Inc. (the “Company”) of his resignation as a director of the Company and as a member of the Nominating and Corporate Governance Committee of the Board, in each case, effective as of the date of the Company's 2023 Annual Meeting of Stockholders.

Dr. O'Donnell's resignation was not the result of any dispute or disagreement with the Company on any matter related to the Company's operations, policies or practices.